This is a phase II study to determine the safety and efficacy of tislelizumab when given in
combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive
bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment
with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles
over 12 weeks followed by transurethral resection biopsy.
High Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.